Clinical Trial Update: An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough [Phase 2]

View source ↗

Summary

The Phase 2 exploratory study of FP01 lozenges in chronic refractory cough has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cough

Drugs mentioned

• FP01 Lozenges (FP01)

Snippet

Sponsor: Avalo Therapeutics, Inc. | Conditions: Chronic Refractory Cough | Phase 2 | Status: COMPLETED